me getting two negatives with that post tells me this board is comprised of mostly ahole shorts....guess the better posters are sitting on the sidelines as I will now do....
guess we'll know sooner or later....I am glad the funding came and should propel Gevo towards profitability....there are certainly some eco minded billionaires who may have dipped their toe into Isobutanol.
almost getting boring to point out how trapped the 'shorts' are at this point. Nothing......thut NOTHING will get them out of the mess they are in.........looks really BAD for the 'SHORTS' at this point....glad I'm not one of them.
Sentiment: Strong Buy
On August 7, 2014, we learned that our request to the FDA for a waiver of the requirement to conduct a thorough QT study with plecanatide had been granted.................
think of it this way....let's just turn off all of Brazill from telecommunication as it's unimportant and unprofitable for this whole country......really???? if you buy into that I've got a title to the Brooklyn Bridge and will sell it to you on the cheap.
yes....all the above is BS.....look at key statistics and realize this company is NOT in the trouble that some shysters are indicating it is....just a bunch of paid liars.
should be over $1 at least.
like a desperate play....time to go up!!!
Again - there's not sure things in this business, but results are generally expected to roll in positive, since Plecanatide shares the same mechanism-of-action with the recently-approved Linzess by Ironwood Pharmaceuticals (IRWD) and partnered with Forest Laboratories (FRX). Synergy has a licensing deal in place for the Linzess mechanism-of-action, should Plecanatide make it to market, nullifying future concerns of patent infringement. Plecanatide is also being investigated for use in treating constipation-predominant irritable bowel syndrome (IBS-C) and the total market targeted by the product could be measures in the billions, leaving plenty of room for both Linzess and Plecanatide to capitalize.
the games being played when it comes to PPS are beyond me....I'm just sticking with the investment in SGYP based on trial results and upcoming data that'll likely be strong positives for SP333 and Plecanatide.
They're really screwing themselves. Longs are just sitting back watching with amusement the nightmare of a situation the shorts have got themselves into.
a shame that these poisons to the stock market continue getting away with their games....SGYP has been one of many (probably) taken down by zealous greedy shorts. I'll stay with SGYP till 2020....hear that shorts??? 2020!!!
sum of the parts litigation....then Gevo has the upperhand over Butamax.....I know most don't understand this post but the future will likely clear this up a bit for you..